These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma. Chatterjee SJ; Datar R; Youssefzadeh D; George B; Goebell PJ; Stein JP; Young L; Shi SR; Gee C; Groshen S; Skinner DG; Cote RJ J Clin Oncol; 2004 Mar; 22(6):1007-13. PubMed ID: 14981105 [TBL] [Abstract][Full Text] [Related]
4. Cyclin D1 expression in transitional cell carcinoma of the bladder: correlation with p53, waf1, pRb and Ki67. Tut VM; Braithwaite KL; Angus B; Neal DE; Lunec J; Mellon JK Br J Cancer; 2001 Jan; 84(2):270-5. PubMed ID: 11161387 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of overexpression of p53 tumor suppressor protein in superficial and invasive transitional cell bladder cancer: comparison with DNA ploidy. Nakopoulou L; Constantinides C; Papandropoulos J; Theodoropoulos G; Tzonou A; Giannopoulos A; Zervas A; Dimopoulos C Urology; 1995 Sep; 46(3):334-40. PubMed ID: 7660508 [TBL] [Abstract][Full Text] [Related]
6. Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma. Shariat SF; Ashfaq R; Sagalowsky AI; Lotan Y J Urol; 2007 Feb; 177(2):481-7; discussion 487. PubMed ID: 17222615 [TBL] [Abstract][Full Text] [Related]
7. Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53. Cote RJ; Dunn MD; Chatterjee SJ; Stein JP; Shi SR; Tran QC; Hu SX; Xu HJ; Groshen S; Taylor CR; Skinner DG; Benedict WF Cancer Res; 1998 Mar; 58(6):1090-4. PubMed ID: 9515785 [TBL] [Abstract][Full Text] [Related]
8. The prevalence and clinicopathologic correlate of p16INK4a, retinoblastoma and p53 immunoreactivity in locally advanced urinary bladder cancer. Tzai TS; Tsai YS; Chow NH Urol Oncol; 2004; 22(2):112-8. PubMed ID: 15082007 [TBL] [Abstract][Full Text] [Related]
9. Predictive value of p53 and pRb expression in superficial bladder cancer patients treated with BCG and interferon-alpha. Esuvaranathan K; Chiong E; Thamboo TP; Chan YH; Kamaraj R; Mahendran R; Teh M Cancer; 2007 Mar; 109(6):1097-105. PubMed ID: 17311305 [TBL] [Abstract][Full Text] [Related]
10. p53 and RB expression predict progression in T1 bladder cancer. Grossman HB; Liebert M; Antelo M; Dinney CP; Hu SX; Palmer JL; Benedict WF Clin Cancer Res; 1998 Apr; 4(4):829-34. PubMed ID: 9563875 [TBL] [Abstract][Full Text] [Related]
11. Different combinations of genetic/epigenetic alterations inactivate the p53 and pRb pathways in invasive human bladder cancers. Sarkar S; Jülicher KP; Burger MS; Della Valle V; Larsen CJ; Yeager TR; Grossman TB; Nickells RW; Protzel C; Jarrard DF; Reznikoff CA Cancer Res; 2000 Jul; 60(14):3862-71. PubMed ID: 10919661 [TBL] [Abstract][Full Text] [Related]
13. p53 expression compared with other prognostic factors in OMS grade-I stage-Ta transitional cell carcinoma of the bladder. Casetta G; Gontero P; Russo R; Pacchioni D; Tizzani A Eur Urol; 1997; 32(2):229-36. PubMed ID: 9286659 [TBL] [Abstract][Full Text] [Related]
14. Abnormal bcl-2 and pRb expression are independent correlates of radiation response in muscle-invasive bladder cancer. Pollack A; Wu CS; Czerniak B; Zagars GK; Benedict WF; McDonnell TJ Clin Cancer Res; 1997 Oct; 3(10):1823-9. PubMed ID: 9815569 [TBL] [Abstract][Full Text] [Related]
15. p53 and p21 Expression levels predict organ preservation and survival in invasive bladder carcinoma treated with a combined-modality approach. Garcia del Muro X; Condom E; Vigués F; Castellsagué X; Figueras A; Muñoz J; Solá J; Soler T; Capellà G; Germà JR Cancer; 2004 May; 100(9):1859-67. PubMed ID: 15112266 [TBL] [Abstract][Full Text] [Related]
16. Pretreatment p53 nuclear overexpression as a prognostic marker in superficial bladder cancer treated with Bacillus Calmette-Guérin (BCG). Saint F; Le Frere Belda MA; Quintela R; Hoznek A; Patard JJ; Bellot J; Popov Z; Zafrani ES; Abbou CC; Chopin DK; de Medina SG Eur Urol; 2004 Apr; 45(4):475-82. PubMed ID: 15041112 [TBL] [Abstract][Full Text] [Related]
17. p53 nuclear accumulation is not associated with decreased disease-free survival in patients with node positive transitional cell carcinoma of the bladder. Fleshner N; Kapusta L; Ezer D; Herschorn S; Klotz L J Urol; 2000 Oct; 164(4):1177-82. PubMed ID: 10992361 [TBL] [Abstract][Full Text] [Related]
18. Prognostic factors in survival of patients with stage Ta and T1 bladder urothelial tumors: the role of G1-S modulators (p53, p21Waf1, p27Kip1, cyclin D1, and cyclin D3), proliferation index, and clinicopathologic parameters. Lopez-Beltran A; Luque RJ; Alvarez-Kindelan J; Quintero A; Merlo F; Requena MJ; Montironi R Am J Clin Pathol; 2004 Sep; 122(3):444-52. PubMed ID: 15362377 [TBL] [Abstract][Full Text] [Related]
19. Predictive value of p53 and pRb immunostaining in locally advanced bladder cancer treated with cystectomy. Jahnson S; Karlsson MG J Urol; 1998 Oct; 160(4):1291-6. PubMed ID: 9751338 [TBL] [Abstract][Full Text] [Related]
20. Evaluation of hypoxia-inducible factor 1alpha overexpression as a predictor of tumour recurrence and progression in superficial urothelial bladder carcinoma. Theodoropoulos VE; Lazaris AC; Kastriotis I; Spiliadi C; Theodoropoulos GE; Tsoukala V; Patsouris E; Sofras F BJU Int; 2005 Feb; 95(3):425-31. PubMed ID: 15679808 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]